CervoMed (CRVO) 10-K 25 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 21, 2016	Jun. 30, 2015
Entity Registrant Name	Diffusion Pharmaceuticals Inc.
Entity Central Index Key	1,053,691
Trading Symbol	dffn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		101,578,512
Entity Public Float			$ 26.2
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 12,006,075	$ 21,883,887
Prepaid expenses, deposits and other assets	169,150	2,286,930
	12,175,225	24,170,817
PROPERTY AND EQUIPMENT, NET	57,995	102,315
OTHER ASSETS
Intangible assets, net	6,449,628	6,449,628
Goodwill	985,000	$ 12,055,991
Investment in Or-Genix	250,000
TOTAL ASSETS	19,917,848	$ 42,778,751
CURRENT LIABILITIES
Accounts payable	36,110	417,307
Other accrued expenses and liabilities	1,167,692	1,921,293
	1,203,802	2,338,600
DEFERRED TAXES	2,274,526	2,274,526
TOTAL LIABILITIES	$ 3,478,328	$ 4,613,126
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Issued and outstanding; $0.001 par value; 1,000,000,000 shares authorized; 2015 - 18,614,968; 2014 - 18,614,968	$ 18,615	$ 18,615
Additional paid-in-capital	115,531,954	113,437,384
Accumulated deficit	(99,111,049)	(75,290,374)
Total stockholders' equity	16,439,520	38,165,625
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 19,917,848	$ 42,778,751

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2012
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	18,614,968	18,614,968
Common stock, shares outstanding (in shares)	18,614,968	18,614,968	890,837

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
EXPENSES
Research and development	$ 3,852,973	$ 2,860,658
General and administrative	7,912,116	$ 4,760,145
Impairment of goodwill	$ 11,070,991
Impairment of other intangible assets		$ 6,670,345
Gain on property damage settlement		(243,592)
Depreciation and amortization	$ 23,269	$ 566,262
Former employee severance expense	967,683
TOTAL EXPENSES	23,827,032	$ 14,613,818
LOSS FROM OPERATIONS	$ (23,827,032)	(14,613,818)
OTHER (INCOME)/EXPENSES
Loss on settlement of notes payable - related parties		1,907,772
Loss on settlement of notes payable		400,016
Other (income) expenses	$ (6,357)	(25,401)
Interest expense		273,503
TOTAL OTHER (INCOME)/EXPENSES	$ (6,357)	2,555,890
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(23,820,675)	(17,169,708)
Benefit from income taxes	0	2,816,884
NET LOSS	$ (23,820,675)	$ (14,352,824)
TOTAL BASIC AND DILUTED LOSS PER SHARE (in dollars per share)	$ (1.28)	$ (1)
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING (in shares)	18,614,968	14,299,473
FULLY-DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING (in shares)	18,614,968	14,299,473

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Paloma [Member]Common Stock [Member]	Paloma [Member]Additional Paid-in Capital [Member]	Paloma [Member]	Vasculo Medics [Member]Common Stock [Member]	Vasculo Medics [Member]Additional Paid-in Capital [Member]	Vasculo Medics [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2013							5,813,785
Balance at Dec. 31, 2013							$ 5,814	$ 67,390,493	$ (60,937,550)	$ 6,458,757
Stock Issued During Period, Shares, New Issues							8,895,685
Issuance of common stock, net of offering costs							$ 8,896	31,841,071		31,849,967
Employee and director stock-based compensation								1,606,947		1,606,947
Warrants issued to consultants								547,061		547,061
Stock Issued During Period, Shares, Acquisitions	2,500,000			220,000
Common stock issued for acquisitions	$ 2,500	$ 6,247,500	$ 6,250,000	$ 220	$ 549,780	$ 550,000
Issuance of common stock to third party for assumption of liabilities (in shares)							150,000
Issuance of common stock to third party for assumption of liabilities							$ 150	272,952		273,102
Retirement of common stock originally issued to a third party for assumption of liabilities (in shares)							(99,332)
Retirement of common stock originally issued to a third party for assumption of liabilities							$ (99)			(99)
Issuance of common stock as settlement of accounts payable and accrued liabilities (in shares)							160,056
Issuance of common stock as settlement of accounts payable and accrued liabilities							$ 160	587,441		$ 587,601
Stock Issued During Period, Shares, Issued to Law Firm in Connection with Conversion of Outstanding Debt							53,457			53,457
Common stock issued as settlement of an outstanding liability to law firm							$ 53	214,112		$ 214,165
Common stock issued as payment of notes payable (in shares)							274,764
Common stock issued as payment of notes payable							$ 275	979,796		980,071
Common stock issued as payment of notes payable - related party (in shares)							646,553
Common stock issued as payment of notes payable - related party							$ 646	3,200,231		3,200,877
Net Income (Loss) Available to Common Stockholders, Basic									(14,352,824)	(14,352,824)
Balance (in shares) at Dec. 31, 2014							18,614,968
Balance at Dec. 31, 2014							$ 18,615	113,437,384	(75,290,374)	38,165,625
Employee and director stock-based compensation								2,095,086		2,095,086
Net Income (Loss) Available to Common Stockholders, Basic									(23,820,675)	(23,820,675)
Balance (in shares) at Dec. 31, 2015							18,614,968
Balance at Dec. 31, 2015							$ 18,615	115,531,954	$ (99,111,049)	16,439,520
Adjustments to Additional Paid in Capital, Change in Fair Value of Warrants Issued								$ (516)		$ (516)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS (USED IN) OPERATING ACTIVITIES
Net loss	$ (23,820,675)	$ (14,352,824)
Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization	23,269	566,262
Loss on disposal of fixed assets	49,278	6,056
Employee and director stock-based compensation - non-cash	2,095,086	1,606,947
Stock warrant expense - noncash	$ 499,003	47,542
Deferred Income Tax Expense (Benefit)		(2,816,884)
Gain on settlement of property damage		$ (243,592)
Impairment of goodwill	$ 11,070,991
Impairment of Intangible Assets (Excluding Goodwill)		$ 6,670,345
Loss on settlement of note payable - related parties		1,907,772
Loss on settlement of note payable		400,016
Changes in other assets and liabilities affecting cash flows from operating activities
Prepaid expenses, deposits and other assets	$ 1,618,261	979,551
Accounts payable and accrued liabilities	(1,134,798)	(3,801,324)
Net cash (used in) operating activities	(9,599,585)	$ (9,030,133)
CASH FLOWS (USED IN) INVESTING ACTIVITIES
Investment in Or-Genix	(250,000)
Purchase of fixed assets	(28,227)	$ (50,911)
Net cash (used in) investing activities	$ (278,227)	(50,911)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES
Proceeds on notes payable - related party		$ 400,000
Proceeds on notes payable
Payment of notes payable		$ (1,540,000)
Proceeds from issuance of common stock net of offering costs		31,849,967
Net cash provided by financing activities		30,709,967
NET (DECREASE) INCREASE CASH AND CASH EQUIVALENTS	$ (9,877,812)	21,628,923
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	21,883,887	254,964
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 12,006,075	21,883,887
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION
Cash paid for interest		677,250
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of accounts payable to notes payable related to Company's outside law firm		407,998
Issuance of shares of common stock and stock warrants as payment of accounts payable and accrued liabilities		1,323,771
Issuance of shares of common stock as payment of notes payable		580,055
Issuance of shares of common stock and stock warrants as payment of notes payable - related parties		1,293,105
Issuance of warrants as payment for consulting services		547,061
Acquisition of business in exchange for common stock		$ 6,800,000

Note 1 - Description of Busines

Note 1 - Description of Business and Corporate History	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business and Corporate History Diffusion Pharmaceuticals Inc. (f/k/a RestorGenex Corporation) (“Company”) is a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology. Unless the context otherwise indicates, all information in these notes relates to the Company during the years ended December 31, 2015 and 2014 and does not reflect the completion of the Merger (as defined below). RestorGenex’s primary product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development in oncology, specifically glioblastoma multiforme. The Company’s current pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. The Company’s novel inhibition of the PI3K/Akt/mTOR pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating innovative therapies that are safe and effective treatments to satisfy unmet medical needs. On January 8, 2016, the Company completed its previously announced merger (“Merger”) with Diffusion Pharmaceuticals LLC (“Diffusion LLC”), and changed its name to Diffusion Pharmaceuticals, Inc. Diffusion LLC is a clinical-stage specialty pharmaceutical company developing new, small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The Company’s lead product candidate, trans sodium crocetinate (“TSC”), uses this novel mechanism to re-oxygenate the microenvironment of solid cancerous tumors, thereby enhancing tumor cells’ response to conventional treatment without additional side effects. See note 17 to the consolidated financial statements for additional information regarding the Merger. On June 18, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware. On March 7, 2014, the Company effected a one-for-100 reverse split of its outstanding common stock. All share data have been adjusted retroactively to reflect the one-for-100 reverse stock split effected on March 7, 2014. On March 3, 2014, the Company entered into an agreement and plan of merger with Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. (“Paloma”) and David Sherris, Ph.D., as founding stockholder and holder representative, pursuant to which the Company agreed to acquire by virtue of a merger all of the outstanding capital stock of Paloma, with Paloma becoming a wholly owned subsidiary of the Company. On March 28, 2014, the merger with Paloma was effected and the Company issued an aggregate of 2,500,000 shares of common stock to the holders of Paloma’s common stock and its derivative securities, which included the assumption of promissory notes of Paloma in the aggregate amount (including both principal amount and accrued interest) of approximately $1,151,725, to be paid on the first anniversary of the closing date of the Paloma merger. For accounting purposes, the acquisition date was deemed to be March 3, 2014, the date the Company assumed oversight and control of the activities of Paloma and VasculoMedics. Also on March 3, 2014, the Company entered into an agreement and plan of merger with VasculoMedics Acquisition, Inc., VasculoMedics, Inc. (“VasculoMedics”) and David Sherris, Ph.D. pursuant to which the Company agreed to acquire by merger all of the outstanding capital stock of VasculoMedics, with VasculoMedics becoming a wholly owned subsidiary of the Company. The VasculoMedics merger was concurrently closed with and as a condition to the closing of the Paloma merger on March 28, 2014 and the Company issued an aggregate of 220,000 shares of common stock to the VasculoMedics stockholders. Effective September 30, 2013, the Company entered into an agreement and plan of merger with Canterbury Acquisition LLC, Hygeia Acquisition, Inc., Canterbury Laboratories, LLC (“Canterbury”), Hygeia Therapeutics, Inc. (“Hygeia”) and Yael Schwartz, Ph.D., as holder representative, pursuant to which the Company agreed to acquire by virtue of two mergers all of the outstanding capital stock of Canterbury and Hygeia, with Canterbury and Hygeia becoming wholly owned subsidiaries of the Company. The consideration paid by the Company in connection with such mergers was the issuance by the Company of an aggregate of 1,150,116 shares of common stock issued to the stakeholders of Canterbury and Hygeia. The mergers were completed on November 18, 2013. For accounting purposes, the acquisition date was deemed to be September 30, 2013, the date the Company assumed oversight and control of the activities of the acquired companies. Prior to the Company repositioning itself as a specialty biopharmaceutical company in 2013, the Company operated various entertainment and sports events which it acquired in a series of acquisitions beginning in March 2008 and operated under the name Stratus Media Group, Inc. until March 7, 2014 when the Company changed its name to RestorGenex Corporation.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation Basis of Presentation These financial statements are expressed in U.S. dollars. The Company is organized into one operating and one reporting segment. The financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Going Concern As of December 31, 2015, the Company had $12,006,075 in cash and cash equivalents. Net cash used in operating activities was $9,599,585 for the year ended December 31, 2015. Net loss for the year ended December 31, 2015 was $23,820,675. As of December 31, 2015, the Company had working capital of $10,971,423. On January 8, 2016, in connection with the Merger described in Note 17, the Company paid $3,261,044 in severance payments to former executives and employees. The Company expects to incur losses for the next several years as it plans to develop its TSC product candidate. The Company is unable to predict the extent of any further losses or when the Company will become profitable, if at all. These financial statements have been prepared under the assumption that the Company will continue as a going concern. Due to the Company’s recurring and expected continuing losses from operations and its present financial resources, the Company has concluded that there is substantial doubt in the Company’s ability to continue as a going concern within one year of issuance on these financial statements without additional capital becoming available to fund planned Phase 2/3 and Phase 3 clinical trials, attain further operating efficiencies and, ultimately, to generate revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company will be required to raise additional capital within the next year to develop its trans sodium crocetinate product candidate and to fund operations at current cash expenditure levels. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business. If the Company is unable to obtain additional financing when needed, (i) it may be required to delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize itself on unfavorable terms.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies Consolidation The consolidated balance sheet at December 31, 2015 and 2014 consolidates the accounts of Canterbury, Hygeia, Paloma, VasculoMedics and ProElite, Inc. The consolidated statements of operations for the year ended December 31, 2015 and 2014 consolidate the accounts of Paloma and VasculoMedics from March 28, 2014, their date of acquisition. All significant intercompany balances were eliminated in consolidation. Use of Estimates The preparation of the Company’s consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. Although these estimates are based on the Company’s knowledge of current events and actions that the Company may undertake in the future, actual results may differ from such estimates and assumptions. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. Fair Value of Financial Instruments The carrying value of certain of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value due to their short maturities. Other information about the Company’s assets and liabilities recorded at fair value is included in note 4. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. The Company records depreciation using the straight-line method over the following estimated useful lives: Equipment ( 3 – 5 Furniture and fixtures ( 5 Leasehold improvements Lesser of lease term or life of improvements Long-Lived Assets Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets may not be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. Business Combinations For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, at their fair values starting in the period when the acquisition is completed. Acquisition-related transaction costs are expensed as incurred. Intangible Assets Intangible assets as of December 31, 2015 and 2014 consisted of an identifiable in-process research and development (“IPR&D”) project intangible asset arising from the acquisition of Paloma. Purchased intangible assets subject to amortization, are reviewed for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. Such events or circumstances include, but are not limited to, a significant decrease in the fair value of the underlying business, a significant decrease in the benefit realized from an acquired business, difficulties or delays in integrating the business or a significant change in the operations of an acquired business. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. An impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be recognized as an impairment charge. Research and development costs incurred after the acquisition are expensed as incurred. Goodwill Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit. The Company performs its annual goodwill impairment test during the fourth quarter of its fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit’s goodwill is less than the carrying value of the reporting unit’s goodwill. Research and Development All research and development costs are expensed as incurred. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities. Stock-Based Compensation Compensation cost is measured and recognized at fair value for all stock-based payments, including stock options. For stock options, the Company estimates fair value using the Black-Scholes option-pricing model, which requires assumptions, such as expected volatility, risk-free interest rate, expected life, and dividends. Stock-based compensation expense is recognized net of estimated forfeitures on a straight-line basis over the related service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior, and is included in general and administrative expenses in the Company’s consolidated statements of operations. For 2015 and 2014, the Company estimated a forfeiture rate of nil when computing stock based compensation expense and reassesses its estimated forfeiture rate periodically based on new facts and circumstances. The Company accounts for equity instruments issued to non-employees in accordance with ASC Topic 718 and Emerging Issues Tax Force (“EITF”) Issue No. 96-18. The fair value of each stock option and warrant granted is estimated as of the grant date using the Black-Scholes option pricing model. Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss attributable to the Company by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if all of the Company’s potential shares, warrants and stock options had been issued and if the additional shares were dilutive. The computation of diluted loss per share does not include the Company’s stock options or warrants as such securities have an antidilutive effect on loss per share. Because of their anti-dilutive effect, 7,793,072 and 8,472,013 shares of the Company’s common stock equivalents comprised of stock options and warrants for the years ended December 31, 2015 and 2014, respectively, have been excluded from the calculation of diluted earnings per share. Comprehensive Income (Loss) The Company does not have items of other comprehensive income (loss) for the years ended December 31, 2015 or 2014; and therefore, comprehensive loss equals net loss for those years. Recently Issued Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “ Revenue from Contracts with Customers ” of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligation in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In July 2015, the FASB delayed the effective date of this guidance. As a result, this ASU will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities have the option of applying either a full retrospective approach or a modified approach to adopt the guidance in the ASU. Although the Company currently does not have any revenues, it is evaluating the impact that this guidance will have on its results of operations, financial position and cash flows. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In February 2016, the FASB issued ASU 2016-02, Leases

Note 4 - Acquisitions

Note 4 - Acquisitions	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Business Combination Disclosure [Text Block]	4. Acquisitions Paloma and VasculoMedics Acquisitions On March 3, 2014, the Company entered into an agreement and plan of merger with Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. and David Sherris, Ph.D., as founding stockholder and holder representative, pursuant to which the Company agreed to acquire by virtue of a merger all of the outstanding capital stock of Paloma, with Paloma becoming a wholly-owned subsidiary of the Company. On March 28, 2014, the merger with Paloma was effected and the Company issued an aggregate of 2,500,000 shares of common stock to the holders of Paloma’s common stock and its derivative securities, which included the assumption of promissory notes of Paloma in the aggregate amount (including both principal amount and accrued interest) of approximately $1,151,725, to be paid on the first anniversary of the closing date of the Paloma merger. On August 5, 2014, the Company repaid in full the then-outstanding balance including accrued interest of the Paloma assumed promissory notes, totaling $1,331,007. The notes were terminated upon their prepayment and there were no early termination fees. Interest expense incurred after acquisition was $179,282. Also on March 3, 2014, the Company entered into an agreement and plan of merger with VasculoMedics Acquisition, Inc., VasculoMedics, Inc. and David Sherris, Ph.D. pursuant to which the Company agreed to acquire by virtue of a merger all of the outstanding capital stock of VasculoMedics, with VasculoMedics becoming a wholly owned subsidiary of the Company. The VasculoMedics merger was concurrently closed with and as a condition to the closing of the Paloma merger on March 28, 2014 and the Company issued an aggregate of 220,000 shares of common stock to the VasculoMedics stockholders. The acquisitions of Paloma and VasculoMedics were additional steps in the implementation of the Company’s plan to position itself as a specialty biopharmaceutical company. The total purchase consideration for the Paloma and VasculoMedics acquisitions was $6,800,000. The transaction has been accounted for using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the intangible assets was the cost approach. The following table summarizes the assets acquired and liabilities assumed as of the acquisition date: Intangibles assets $ 6,449,628 Prepaids and other current assets 23,642 Property, plant and equipment 58,123 Goodwill 3,829,858 Accrued liabilities (135,000 ) Notes payable and accrued interest (1,151,725 ) Deferred tax liability (2,274,526 ) Net assets acquired $ 6,800,000 For the year ended December 31, 2014, expenses associated with the Paloma and VasculoMedics acquisitions were $846,910 included in the consolidated net loss of $14,352,824 for the year ended December 31, 2014. Acquisition-related costs related to the Paloma and VasculoMedics acquisitions were nominal. Due to the timing of this acquisition, it did not have a material impact on the Company’s financial statements. As such, the Company has not presented pro forma disclosures.

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment, Net Property and equipment, net of accumulated depreciation at December 31, 2015 and 2014 consists of the following : December 31, 2015 2014 Computing equipment and office machines $ 38,785 $ 16,072 Furniture and fixtures 35,196 32,945 Leasehold improvements 5,157 60,017 Total 79,138 109,034 Less accumulated depreciation (21,143 ) (6,719 ) Property and equipment, net $ 57,995 $ 102,315 For the year ended December 31, 2015, depreciation expense was $23,269. For the year ended December 31, 2014, depreciation expense was $11,924. For the years ended December 31, 2015 and 2014, the Company disposed of certain property and equipment, resulting in a loss on disposal of $49,278 and $6,056, respectively, which is included within general and administrative expenses on the condensed consolidated statements of operations.

Note 6 - Intangible Assets, Net

Note 6 - Intangible Assets, Net	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	6. Intangible Assets, Net Intangible assets were as follows: December 31, 2015 December 31, 2014 Gross Carrying Amount Accumulated Amortization Intangible Assets, net Gross Carrying Amount Accumulated Amortization Intangible Assets, net In-process research and development costs (IPR&D) $ 6,449,628 $ — $ 6,449,628 $ 6,449,628 $ — $ 6,449,628 During the second quarter of 2015, the Company performed its annual review for impairment of IPR&D intangible asset as prescribed in ASC 350 and determined that there had been no impairment to this asset. In connection with an impairment of the Company’s goodwill as discussed in note 7 below, the Company re-assessed the IPR&D asset for impairment and concluded there was no impairment of the IPR&D asset for the year ended December 31, 2015. For the years ending December 31, 2015 and 2014, the Company recorded amortization expense on finite lived intangible assets of $0 and $554,338, respectively, within depreciation and amortization on the consolidated statements of operations. In the fourth quarter of 2014, the Company strategically decided that its initial focus would be its development efforts with respect to RES-529 on ophthalmology (specifically age-related macular degeneration) and oncology (specifically glioblastoma multiforme) and RES-440 on dermatology (specifically acne vulgaris). Based on the Company’s decision to abandon its development efforts on the Canterbury cosmeceutical finite lived intangible assets and the Canterbury IPR&D asset, the Company determined that the carrying value of such assets was no longer recoverable. The Company recorded an impairment of its intangible assets of $6,670,345 on its consolidated statements of operations as of December 31, 2014. The impairment consisted of $3,035,000 of impairment of the IPR&D asset and $3,635,345 of impairment of finite lived intangible assets.

Note 7 - Goodwill

Note 7 - Goodwill	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Goodwill Disclosure [Text Block]	7. Goodwill Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. The Company applies ASC 350 “ Goodwill and Other Intangible Assets The Company considers certain triggering events when evaluating whether an interim goodwill impairment analysis is warranted. Among these would be a significant long-term decrease in the market capitalization of the Company based on events specific to the Company’s operations. The Company’s market capitalization decreased significantly during second and third quarters of 2015 as the Company’s share price declined from $2.80 per share as of April 30, 2015 to $0.90 per share as of September 30, 2015. As of September 30, 2015, the Company’s market capitalization was approximately $16.7 million, falling to an amount significantly less than the Company’s stockholders’ equity. In September 2015, management concluded that given the significant and sustained decrease in the Company’s share price to a level below its stockholders’ equity at that time, combined with information on the Company’s fair value derived from strategic discussions with third parties during the third quarter of 2015, a triggering event requiring an interim assessment of goodwill impairment had occurred during the third quarter of 2015. Management performed the goodwill impairment assessment using a market approach to estimating the fair value of the Company, using multiple inputs, some weighted heavier than others. The inputs included the Company’s market capitalization at that time, which, based on the inactive trading activity in the Company’s stock, was a lower level input on the fair value measurement hierarchy, and other more heavily weighted unobservable inputs as to the Company’s fair value derived from strategic discussions with third parties. The initial step one assessment indicated that it was likely the Company’s goodwill was impaired, and the Company proceeded to perform step two of its goodwill impairment assessment. As a result of that assessment, the Company concluded that a goodwill impairment loss of $11,070,991 was necessary. Following the recording of the goodwill impairment loss, the Company’s goodwill as of September 30, 2015 was $985,000. An annual impairment review was most recently completed on December 31, 2015. As of the December 31, 2015 impairment review, there was no additional impairment loss associated with recorded goodwill as the estimated fair value exceeded the carrying amount. The fair value of the reporting unit as of December 31, 2015, for the purpose of assessing the impairment of goodwill, was determined based on a qualitative assessment, utilizing the most recent baseline valuation that occurred on September 30, 2015, the market capitalization trend since the baseline valuation, and the then recently announced merger with Diffusion Pharmaceuticals LLC (See note 17 to the consolidated financial statements). The Company determined that it was more likely than not that the fair value of its businesses for accounting purposes exceeded the carrying amount, and therefore, indicated no impairment of goodwill. Following the December 31, 2015 annual impairment review of the goodwill, the Company’s goodwill as of December 31, 2015 was $985,000.

Note 8 - Other Accrued Expenses

Note 8 - Other Accrued Expenses and Liabilities	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	8. Other Accrued Expenses and Liabilities Other accrued expenses and liabilities consisted of the following: December 31, 2015 2014 Payroll related $ 91,302 $ 741,032 Professional fees 101,151 217,663 Board fees 55,938 55,000 Rent liability for facilities no longer occupied 424,155 808,418 Severance 221,183 0 Franchise taxes 97,644 0 Other 176,319 99,180 $ 1,167,692 $ 1,921,293

Note 9 - Stockholder's Equity

Note 9 - Stockholder's Equity	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Stockholder’s Equity Preferred Stock The Company has 5,000,000 shares of authorized, but unissued shares of preferred stock with a par value of $0.001 per share. Common Stock The Company has 1,000,000,000 shares of authorized common stock with a par value of $0.001 per share, of which 18,614,968 shares are issued and outstanding as of December 31, 2015. Private Placements On April 29, 2014, the Company issued to various institutional and individual accredited investors an aggregate of 2,776,500 shares of common stock and four-year warrants to purchase an aggregate of 832,950 shares of common stock. The price of each unit, which consisted of one share of common stock plus a warrant to purchase 0.3 share of common stock was $4.00. The exercise price of the warrant is $4.80 per share. In addition, on April 29, 2014, the Company issued to its placement agent as part of its compensation warrants to purchase 277,650 shares of common stock, on substantially the same terms as the warrants issued to investors. Also, on April 29, 2014, the Company issued a warrant to purchase 35,000 shares of common stock to its placement agent as compensation for a debt conversion transaction. The exercise price of the warrant is $4.80 per share. On May 6, 2014, the Company issued to various institutional and individual accredited investors an aggregate of 3,418,125 shares of common stock and four-year warrants to purchase an aggregate of 1,025,438 shares of common stock. The price of each unit, which consisted of one share of common stock plus a warrant to purchase 0.3 share of common stock was $4.00. The exercise price of the warrant is $4.80 per share. In addition, on May 6, 2014, the Company issued to its placement agent as part of its compensation warrants to purchase 341,813 shares of common stock, on substantially the same terms as the warrants issued to investors. On May 21, 2014, the Company issued to various institutional and individual accredited investors an aggregate of 872,310 shares of common stock and four-year warrants to purchase an aggregate of 261,693 shares of common stock. The price of each unit, which consisted of one share of common stock plus a warrant to purchase 0.3 share of common stock was $4.00. The exercise price of the warrant is $4.80 per share. In addition, on May 21, 2014, the Company issued to its placement agent as part of its compensation warrants to purchase 89,731 shares of common stock, on substantially the same terms as the warrants issued to investors. 94 On June 13, 2014, the Company issued to various institutional and individual accredited investors an aggregate of 1,778,750 shares of common stock and four-year warrants to purchase an aggregate of 533,625 shares of common stock. The price of each unit, which consisted of one share of common stock plus a warrant to purchase 0.3 share of common stock was $4.00. The exercise price of the warrant is $4.80 per share. In addition, on June 13, 2014, the Company issued to its placement agent as part of its compensation warrants to purchase 177,875 shares of common stock, on substantially the same terms as the warrants issued to investors. On July 10, 2014, the Company issued to various institutional and individual accredited investors an aggregate of 50,000 shares of common stock and four-year warrants to purchase an aggregate of 15,000 shares of common stock. The price of each unit, which consisted of one share of common stock plus a warrant to purchase 0.3 share of common stock was $4.00. The exercise price of the warrant is $4.80 per share. In addition, on June 13, 2014, the Company issued to its placement agent as part of its compensation warrants to purchase 5,000 shares of common stock, on substantially the same terms as the warrants issued to investors. Gross proceeds of the private placement to the Company were approximately $35.6 million and net proceeds were approximately $31.9 million, after paying $3.6 million of placement agent fees and $0.1 million of offering expenses. The Company filed a registration statement on Form S-1 with the SEC on July 14, 2014 registering the offering and resale of 11,633,885 shares of common stock, including the outstanding shares of common stock and shares of common stock issuable upon exercise of the warrants issued in the private placement. This registration statement was declared effective by the SEC on July 31, 2014. Common Stock Issued in Settlement of Obligations On April 29, 2014, the Company issued to its then Chairman of the Board 546,553 shares of common stock and a warrant to purchase 351,060 shares of common stock at an exercise price of $2.00 per share upon conversion of four convertible promissory notes in the aggregate principal amount of $1,050,000 issued by the Company. The Company recorded a loss on this conversion in the amount $1,650,378. On May 21, 2014 the Company issued 259,236 shares of common stock to a creditor upon conversion of a promissory note in the principal amount of $500,000. On December 2, 2014, the Company issued 7,764 shares of common stock to two creditors upon conversion of promissory notes in the principal amount of $50,000. The Company recorded a loss on these settlements in the amount of $400,016. The Company issued an aggregate of 160,056 shares of common stock to creditors, former directors and a former officer, pursuant to settlements of outstanding liabilities then owed to such individuals, and 53,457 shares of common stock and a warrant to purchase 16,037 shares of common stock as part of a settlement of outstanding amounts due to the law firm. On October 21, 2014, the Company issued to a then member of the Company’s Board of Directors 100,000 shares of common stock and a warrant to purchase 75,000 shares of common stock at an exercise price of $4.80 per share upon conversion of a note payable in the principal amount of $200,000 issued by the Company. The Company recorded a loss on this conversion in the amount $257,394. Stock Options Options to purchase an aggregate of 3,011,498 shares of common stock were outstanding as of December 31, 2015, and options to purchase an aggregate of 1,861,952 shares of common stock were exercisable as of December 31, 2015. During the year ended December 31, 2014, the Company issued options to purchase an aggregate of 438,131 shares, respectively, of common stock to non-employee members of the Company’s Board of Directors at a weighted average exercise price of $3.70 per share. These options have a ten-year term and vest in equal quarterly installments over three years. No such options were issued in 2015. During the years ended December 31, 2015 and 2014, the Company issued options to purchase an aggregate of 6,650 and 2,849,050 shares of common stock to employees of the Company at a weighted average exercise price of $1.90 and $3.70 per share. These options have a ten-year term and vest in equal quarterly installments over three years. 95 Warrants Warrants to purchase an aggregate of 4,781,574 shares of the Company’s common stock were outstanding and exercisable as of December 31, 2015: Number of Underlying Shares of Common Stock February 2, 2011 2,000 100.00 February 2, 2016 February 23, 2011 1,500 100.00 February 23, 2016 March 15, 2011 1,200 100.00 March 15, 2016 April 6, 2011 2,000 100.00 April 6, 2016 April 15, 2011 1,200 100.00 April 15, 2016 April 26, 2011 2,500 100.00 April 26, 2016 April 29, 2011 3,000 100.00 April 29, 2016 June 26, 2011 104,057 65.00 June 26, 2016 June 26, 2011 52,028 100.00 June 26, 2016 July 1, 2011 5,300 65.00 July 1, 2016 May 23, 2012 30,000 30.00 May 23, 2017 July 1, 2012 10,000 75.00 July 1, 2017 August 20, 2012 90,000 38.00 August 20, 2017 March 27, 2013 173,917 3.00 March 27, 2018 March 17, 2014 15,000 4.90 March 17, 2019 April 29, 2014 832,950 4.80 April 29, 2018 April 29, 2014 277,650 4.80 April 29, 2018 April 29, 2014 35,000 4.80 April 29, 2018 April 29, 2014 351,060 2.00 April 29, 2018 May 6, 2014 1,025,438 4.80 May 6, 2018 May 6, 2014 341,813 4.80 May 6, 2018 May 21, 2014 261,693 4.80 May 21, 2018 May 21, 2014 89,731 4.80 May 21, 2018 June 13, 2014 533,625 4.80 June 13, 2018 June 13, 2014 177,875 4.80 June 13, 2018 June 13, 2014 16,037 4.80 June 13, 2018 July 10, 2014 15,000 4.80 July 10, 2018 July 10, 2014 5,000 4.80 July 10, 2018 October 21, 2014 75,000 4.80 October 21, 2018 December 8, 2014 250,000 3.75 December 8, 2019 4,781,574 During the year ended December 31, 2014, the Company issued to investors in its private placement warrants to purchase an aggregate of 2,668,706 shares of common stock at an exercise price of $4.80 per share and to the placement agent in the private placement as partial consideration for its services in connection with the private placement warrants to purchase an aggregate of 892,069 shares of common stock at an exercise price of $4.80 per share. The Company also issued the placement agent a warrant to purchase 35,000 shares of common stock at an exercise price of $4.80 per share as compensation for a debt conversion transaction. These warrants have a four-year term and were immediately vested and exercisable as of the date of grant. 96 In addition, during the year ended December 31, 2014, the Company issued to its then Chairman of the Board a warrant to purchase 351,060 shares of common stock at an exercise price of $2.00 per share in addition to 546,553 shares of common stock upon conversion of four convertible promissory notes of the Company in the aggregate principal amount of $1,050,000. See note 13 to the consolidated financial statements. This warrant has a four-year term and was immediately vested and exercisable as of the date of grant, resulting in Black-Scholes fair value of $803,221 included within “settlement loss on notes payable – related parties” on the consolidated statements of operations during the year ended December 31, 2014. In addition, during the year ended December 31, 2014, the Company issued a warrant to purchase 75,000 shares of common stock at an exercise price of $4.80 per share in addition to 100,000 shares of common stock to a member of the Company’s Board of Directors upon conversion of a non-interest bearing and unsecured note in the principal amount of $200,000. See note 13 to the consolidated financial statements. This warrant has a four-year term and was immediately vested and exercisable as of the date of grant, resulting in Black-Scholes fair value of $107,395 included within “settlement loss on notes payable – related parties” on the consolidated statements of operations during the year ended December 31, 2014. In addition, during the year ended December 31, 2014, the Company issued to a law firm a four-year warrant to purchase 16,037 shares of common stock at an exercise price of $4.80 as part of a settlement of outstanding amounts due to the law firm. This warrant has a four-year term and was immediately vested and exercisable as of the date of grant, resulting in Black-Scholes fair value of $24,393 included within “general and administrative expenses” on the consolidated statements of operations during the year ended December 31, 2014. In addition, during the year ended December 31, 2014, the Company issued to an independent consultant a warrant to purchase 15,000 shares of common stock at an exercise price of $4.90 in consideration for services. This warrant has a five-year term and vested in monthly installments over one year, resulting in 15,000 vested shares and a Black-Scholes warrant expense of $25,976 during the year ended December 31, 2014 and a mark to market adjustment of $516 during the year ended December 31, 2015. In addition, during the year ended December 31, 2014, the Company issued to its investor relations firm a warrant to purchase 250,000 shares of common stock at an exercise price of $3.75 in consideration for investor relations services for one year, which commenced on December 15, 2014 and ended in 2015. This warrant has a five-year term and was immediately vested and exercisable as of the date of grant, resulting in Black-Scholes warrant value of $517,576, of which $496,010and $21,566 was expensed in general and administrative expenses during the years ended December 31, 2015 and 2014. The Company estimates the fair value of warrants using a Black-Scholes model that considers assumptions noted in the table below: 2014 Risk-free interest rate 1.11 – 1.67% Expected life in years 4.0 – 5.0 Expected volatility 64% - 66% Expected dividend yield —

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. Stock-Based Compensation On March 5, 2015, the Company’s Board of Directors approved the RestorGenex Corporation 2015 Equity Incentive Plan (the “2015 Equity Plan”), and on June 17, 2015, the Company’s stockholders approved the 2015 Equity Plan. The 2015 Equity Plan allows for the issuance of up to a maximum of 2,500,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate. In addition, the Company has granted several non-plan options. As of December 31, 2015, a total of 3,004,848 and 2,500,000 were authorized under non-plan options and the 2015 Equity Plan, respectively, and the Company had 0 and 2,493,350 shares of common stock available under the non-plan options and 2015 Equity Plan. Options are granted with exercise prices equal to the fair value of the common stock on the date of grant. The Company recognizes the fair value of stock-based awards granted in exchange for employee and non-employee services as a cost of those services. The Company recognizes stock-based compensation expense for option awards on a straight-line basis over the vesting period. The following table summarizes the stock option compensation expense for employees and non-employees recognized in the Company’s consolidated statements of operations for the period: December 31, 2015 December31, 2014 Research and development $ 597,554 $ 526,331 General and administrative 1,497,532 1,080,616 Total stock-based compensation expense $ 2,095,086 $ 1,606,947 The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of estimates, including the expected life of stock options, expected stock price volatility, the risk-free interest rate and the expected dividend yield. The Company calculates the expected life of stock options using the “simplified method” described in Staff Accounting Bulletin (“SAB”) Topic 14, Share-Based Payment The Company uses historical data when available to estimate pre-vesting option forfeitures, and records stock-based compensation expense only for those awards that are expected to vest. The weighted-average fair value of the Company’s options granted to employees was $1.90 and $3.71 per share, in 2015 and 2014, respectively. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions: 2015 2014 Risk-free interest rate 1.84% 1.82% - 2.03% Expected life in years 6.0 6.0 Expected volatility 68% 70% - 71% Expected dividend yield — — Stock options outstanding that have vested or are expected to vest as of December 31, 2015 were as follows: Shares of Common Stock Weighted- Average Per Share Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Vested 1,861,953 $ 4.22 6.7 $ - Expected to vest 1,149,545 3.69 8.5 - Total 3,011,498 $ 4.01 7.4 $ - The aggregate intrinsic value amounts represent the difference between the exercise price and $1.00, the fair value of our common stock on December 31, 2015, for in-the-money options. A summary of the Company’s employee stock option activity is as follows: Outstanding Exercisable Number of Shares Weighted- Average Per Share Exercise Price Weighted- Average Remaining Contractual life (in years) Number of Shares Weighted- Average Per Share Exercise Price Weighted- Average Remaining Contractual life (in years) Outstanding at January 1, 2014 389,436 $ 11.77 3.9 367,110 $ 11.10 3.9 Granted 3,287,181 3.71 Exercised — — Forfeited or expired (28,370 ) 33.99 Outstanding at December 31, 2014 3,648,247 $ 5.44 8.8 1,072,111 $ 9.49 7.2 Granted 6,650 1.90 Exercised — — Forfeited or expired (643,399 ) 6.28 Outstanding at December 31, 2015 3,011,498 $ 4.01 7.4 1,861,952 $ 4.22 6.7 The completion of the Merger on January 8, 2016, as discussed in note 17, constituted a “change in control” under the Company’s non-plan option agreements thereby resulting in automatic acceleration of vesting of all options outstanding as of the effective time of the Merger and such options remaining exercisable for the remainder of their terms. As of December 31, 2015, the Company had $2,675,669 of total unrecognized compensation cost related to unvested stock-based compensation arrangements granted to employees. That cost was recognized in January 2016 due to the acceleration of vesting triggered by the Merger as explained above. Per share exercise prices for options outstanding at December 31, 2015 and 2014, ranged from $1.90 to $54.00.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and Contingencies Office Space Rental On September 4, 2014, the Company entered into a lease agreement for office space totaling approximately 2,900 square feet in Buffalo Grove, Illinois and relocated its corporate headquarters to this facility in the third quarter of 2014. The term of the lease commenced on September 15, 2014 and will continue through February 28, 2018. The Company has an option to renew the lease for one renewal term of three years. Under the lease agreement, the first five months are rent free and then the base rent will be approximately $6,000 per month through February 28, 2016 for a total of approximately $72,000 per year. The base rent will increase to approximately $6,100 per month for the first year thereafter and $6,200 per month for the second year thereafter. The Company’s contractual obligations with respect to rental commitments as of December 31, 2015 were as follows: Rental Commitments Payments due by period: One year $ 72,920 Two years 74,355 Three years 12,432 Four years — Five years — Over five years — Total $ 159,707 Purchase Obligations As of December 31, 2015, the Company had no material future commitments in regards to the preclinical development of RES-440 and RES-529. Litigation From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its condensed consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, where the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of December 31, 2015, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company’s consolidated results of operations, financial position or cash flows. On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company’s former Chief Executive Officer under the caption Paul Feller v. RestorGenex Corporation, Pro Sports & Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH On September 21, 2015, David Schmidt, a member of Diffusion, filed suit (the “Complaint”) in the Circuit Court for Albemarle County (Virginia), which is proceeding as Case. No. CL15-791, David G. Schmidt v. Diffusion Pharmaceuticals, LLC Diffusion filed a Demurrer asking the court to dismiss the Complaint for failing to state a viable cause of action. Diffusion maintains that neither the convertible promissory note nor the operating agreement entitle Mr. Schmidt to receive a lower conversion price that was negotiated with other noteholders after he elected to convert his notes. Diffusion also seeks dismissal of the other claims on various grounds, including the economic loss rule (which generally prohibits tort claims arising out of a breach of contract) and the statute of limitations. A hearing on Diffusion’s Demurrer was held on March 14, 2016, at which hearing the claim was dismissed for failing to state a viable cause of action. Mr. Schmidt has up to 21 days to file an amended, restated complaint. Management and legal counsel for Diffusion are of the opinion that the plaintiff’s claim is without merit and Diffusion will prevail in defending the suit. Diffusion is unable to estimate the possible loss or range of loss should Diffusion not prevail in defending the suit.

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Taxes Significant components of the Company's deferred tax assets for federal income taxes consisted of the following: December 31, Deferred Tax Assets 2015 2014 Net operating loss carryforwards $ 25,165,014 $ 23,030,884 Stock option compensation 6,937,512 6,083,848 Other — 26,783 Valuation allowance (32,102,526 ) (29,141,515 ) Net deferred tax asset $ — $ — Deferred Tax Liabilities Intangible assets $ (2,274,526 ) $ (2,274,526 ) During the year ended December 31, 2014, in conjunction with the accounting associated with the Paloma acquisition described in note 4 to the consolidated financial statements, the Company recorded a deferred tax liability related to tax basis differences associated with the acquired indefinite lived IPR&D intangible asset. As the entire deferred tax liability as of December 31, 2015 and 2014 relates to an indefinite lived intangible asset, which due to its indefinite life will not serve as reversible temporary differences that give rise to future taxable income; the Company maintains a full valuation allowance on its deferred tax assets, resulting in a net deferred tax liability position equal to the deferred tax liability on the Company’s indefinite lived intangible asset. 101 The Company has no current tax provision due to its current and accumulated losses, which result in net operating loss carryforwards. The Company recorded a deferred tax benefit of $2,816,884 in the consolidated statements of operations for the year ended December 31, 2014 due primarily to the reduction in the Company’s intangible assets resulting from the impairment loss on such assets recorded in 2014 and the amortization recorded on a portion of those impaired intangible assets prior to the date of the impairment. The Company had net operating loss carry-forwards (“NOL”) for federal and state income tax purposes of approximately: December 31, 2015 2014 Combined NOL Carryforwards: Federal $ 63,013,194 $ 57,521,560 State 54,131,507 50,440,965 The net operating loss carryforwards begin expiring in 2020 for Federal income tax purposes and 2016 for state income tax purposes. From December 31, 2012 to December 31, 2015, the number of outstanding shares of our common stock increased from 890,837 to 18,614,968. In January 2016, the number of outstanding shares of common stock further increased to 101,578,512 following completion of the Merger discussed in note 17. This increase in the number of shares outstanding constitutes a change of ownership, under the provisions of Internal Revenue Code Section 382 and similar state provisions, and is likely to significantly limit the Company’s ability to utilize these net operating loss carryforwards to offset future income. Accordingly, the Company recorded a 100% valuation allowance of the deferred tax assets as of December 31, 2015 and December 31, 2014 because of the uncertainty of their realization. A reconciliation of the income tax rate computed at the federal statutory rate to that recorded in the financial statements for 2015 and 2014 is as follows: 2015 2014 Rate reconciliation: Federal tax benefit at statutory rate $ (8,337,236 ) (35.0 %) $ (6,009,398 ) (35.0 %) State tax, net of Federal benefit (1,368,216 ) (5.7 %) (986,051 ) (5.7 %) Change in valuation allowance 2,961,011 12.4 % 2,866,582 10.9 % Goodwill impairment 4,510,986 18.9 % — — Other 2,233,455 9.4 % 1,311,983 13.4 % Total provision $ — 0.0 % $ (2,816,884 ) (16.4 %)

Note 13 - Employee Benefit Plan

Note 13 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	13. Employee Benefit Plan The Company sponsors a defined contribution 401(k) retirement savings plan (the “401(k) Plan”) covering all of its employees. Employee contributions to the 401(k) Plan are voluntary. Participants’ contributions are limited to their annual tax deferred contribution limit as allowed by the Internal Revenue Service. There were matching contributions of $22,950 and $0 for the years ended December 31, 2015 and 2014, respectively. The Company terminated the 401(k) Plan in connection with the Merger. See note 17 to the consolidated financial statements.

Note 14 - Basic and Diluted Net

Note 14 - Basic and Diluted Net Loss Per Share	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Earnings Per Share [Text Block]	14. Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if all of the Company’s potential shares, warrants and stock options had been issued and if the additional shares are dilutive. Because of their anti-dilutive effect, all stock options and warrants for the years ended December 31, 2015 and 2014, respectively, have been excluded from the calculation of diluted net loss per share. Years Ended 2015 2014 Basic and dilutive numerator: Net loss, as reported $ (23,820,675 ) $ (14,352,824 ) Denominator: Weighted-average shares outstanding 18,614,968 14,299,473 Net loss per share - basic and diluted $ (1.28 ) $ (1.00 )

Note 15 - Investment in Or-Geni

Note 15 - Investment in Or-Genix Therapeutics, Inc.	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Investment [Text Block]	15. Investment in Or-Genix Therapeutics, Inc. In April 2015, the Company entered into several agreements with Or-Genix Therapeutics, Inc. (“Or-Genix”), pursuant to which the Company transferred certain of its non-focus technology rights to Or-Genix in exchange for a 19.9% ownership interest in Or-Genix, representing 2,484,395 shares of the common stock of Or-Genix, and purchased $250,000 in perpetual non-redeemable preferred stock which is included in other assets as of December 31, 2015. The rights the Company transferred include exclusive rights to a compound formerly known as “RES-102,” which is a “soft” estrogen potentially to be developed for the treatment of aging skin fragility/thinning and vulvo-vaginal atrophy, and exclusive rights to a compound formerly known as “RES-214,” a non-prescription cosmeceutical product under development by a sublicensee. The Company previously licensed these rights from Yale University and as part of this transaction assigned those license agreements to Or-Genix. The Company also assigned its rights under a sublicense agreement with Ferndale Pharma Group, Inc. for the formulation, manufacture, sale and marketing of RES-214. As the rights exchanged for the common stock investment had a recorded value of zero as of the transaction date, and as the common stock transaction was a non-monetary exchange, no value was assigned to the common stock portion of the Company’s Or-Genix investment and no gain or loss was recognized as a result of the transaction. Or-Genix is founded and owned primarily by Yael Schwartz, Ph.D., a former member of the Company’s Board of Directors and former Executive Vice President, Preclinical Development. The transfer of these technology rights to Or-Genix was executed since the Company is focusing its development efforts and resources on its other technologies. The Company does not control nor exercise significant influence over Or-Genix.

Note 16 - Former Employee Sever

Note 16 - Former Employee Severance Expense	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Former Employee Severance Expense [Text Block]	16. Former Employee Severance Expense On April 30, 2015, the Company entered into resignation agreements with the Company’s former Executive Vice President, Preclinical Development and former Vice President of Pharmaceutical Sciences. As part of these resignation agreements, the Company modified their stock option agreements to provide for continued vesting until June 30, 2015 and to extend the post-termination exercise period from 90 days to one year, resulting in a minimal amount of additional stock-based compensation expense. On June 19, 2015, the Company entered into a resignation agreement with the Company’s former Chief Scientific Officer. Costs associated with the resignation agreements, consisting primarily of severance-related charges, are reflected in the former employee severance expense section in the condensed consolidated statement of operations for the year ended December 31, 2015. $221,183 related to these charges was included in other accrued liabilities as of December 31, 2015.

Note 17 - Subsequent Event

Note 17 - Subsequent Event	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	17. Subsequent Event Merger with Diffusion LLC On January 8, 2016, the Company, through a subsidiary, completed the Merger with and into Diffusion LLC pursuant to the Merger Agreement and, as a result, Diffusion LLC became a wholly-owned subsidiary of the Company creating a combined company that is a clinical stage biotechnology company focused on developing therapeutics for the treatment of certain cancers. In connection with the Merger, the Company issued to the holders of outstanding units of Diffusion LLC an aggregate of 82,963,544 shares of Common Stock and, as a result, immediately following the completion of the Merger, the former equity holders of Diffusion LLC owned approximately 84.1% of the Common Stock of the Company and the stockholders of RestorGenex immediately prior to the Merger owned approximately 15.9% of the Common Stock of the combined company, in each case, on a fully-diluted basis (subject to certain exceptions and adjustments). Also in connection with the Merger, the pre-Merger directors and officers of the Company tendered their resignations and the pre-Merger directors and officers of Diffusion LLC were appointed as the new directors and officers of the Company, and our corporate headquarters moved from Buffalo Grove, Illinois to Charlottesville, Virginia. Following the completion of the Merger, the Company changed its corporate name from “RestorGenex Corporation” to “Diffusion Pharmaceuticals Inc.” and changed the trading symbol of the Company’s common stock from “RESX” to “DFFN.” At the effective time of the Merger, each outstanding unit of membership interest of Diffusion (“Diffusion Units”) was converted into the right to receive 3.652658 shares of the Company’s common stock, as determined pursuant to the Merger Agreement (“Exchange Ratio”). Also at the effective time of the Merger, $1,125,000 of Diffusion convertible notes were outstanding and the rights of the holders of each outstanding convertible promissory note convertible into Diffusion Units (“Diffusion Convertible Notes”) was converted into the right to convert such securities into a number of shares of the Company’s common stock equal to the number of Diffusion Units such Diffusion Convertible Note would be convertible into pursuant to its terms multiplied by the Exchange Ratio. In addition, at the effective time of the Merger and as a result of the Merger, all outstanding options to purchase Diffusion Units were converted into and became options to purchase the Company’s common stock on terms substantially identical to those in effect prior to the effective time of the Merger, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio. As a result of the Merger, and taking into account the adjustments to the number of shares and exercise price as a result of the Merger, we assumed options to purchase Diffusion Units which converted into options to purchase an aggregate of 14,952,101 shares of the Company’s common stock with a weighted average exercise price of $0.40 per share. No fractional shares of the Company’s common stock were issued in connection with the Merger, and holders of Diffusion Units received cash in lieu thereof. For accounting purposes, the Merger is treated as a “reverse acquisition” under generally acceptable accounting principles in the United States (“U.S. GAAP”) and Diffusion LLC is considered the accounting acquirer. Accordingly, Diffusion LLC’s historical results of operations will replace the Company’s historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the results of operations of the combined company will be included in the Company’s financial statements. During 2015, the Company incurred transaction costs of $1,193,115 in connection with the Merger that were incurred and expensed within “general and administrative expenses” on the consolidated statements of operations during the year ended December 31, 2015. The completion of the Merger constituted a “change in control” under the Company’s non-plan option agreements thereby resulting in automatic acceleration of vesting of all options outstanding as of the effective time of the Merger and such options remaining exercisable for the remainder of their terms. In addition, because of the termination of employment of the Company’s officers and employees in connection with the Merger, the Company incurred approximately $3,039,860 in severance costs during the first quarter of 2016, which amounts were paid to the affected employees in January 2016. Contingent Value Rights Distribution Prior to the effective time of the Merger, the Company’s Board of Directors authorized, declared and effected a distribution of contingent value rights (“CVRs”) to existing stockholders of the Company as of the close of business on January 7, 2016 (the “CVR Record Date”) at a rate of one CVR for each share of the Company’s common stock. The CVRs, which are not certificated and not attached to the shares of the Company’s common stock, were payable immediately prior to the effective time. Each CVR represents a non-transferable right (subject to certain limited exceptions) to potentially receive certain cash payments in the event the Company receives net cash payments during the five-year period after the Merger as a result of the sale, transfer, license or similar transaction relating to the Company’s product currently known as RES-440, which is a “soft” anti-androgen, upon the terms and subject to the conditions set forth in a contingent value rights agreement, dated January 8, 2016, between the Company and Computershare, Inc., as rights agent (the “CVR Agreement”). The aggregate cash payments to be distributed to the holders of the CVRs, if any, will be equal to the amount of net cash payments received by the Company as a result of the sale, transfer, license or similar transaction relating to RES-440, as determined pursuant to the CVR Agreement, but will not exceed $50 million in the aggregate. Any option or warrant holder of the Company as of the record date for the CVRs would, at the time of exercise, be entitled to receive one CVR for each share of the Company’s common stock issued upon the future exercise of the option or warrant, which would entitle the holder to a pro rata portion of any CVR payments made after the date of exercise. Voting and Lock-Up Agreements On January 8, 2016, the Company entered into a voting and lock-up agreement with each of the pre-closing directors and executive officers of the Company and Diffusion, who collectively held approximately 16.6% of the outstanding common stock of the combined company after the Merger, pursuant to which such persons agreed, for six months after the Merger, to vote all of their respective shares of common stock owned after the Merger for such proposals that are reasonably presented by the Company’s Board of Directors and to not sell, pledge, encumber or take certain other actions with respect to such shares. Assumption of Diffusion Indebtedness As a result of the Merger, all of the outstanding indebtedness of Diffusion became the obligation of the Company. As of the closing date of the Merger, there was $1,125,000 of principal amount of notes outstanding (the “Notes”) with an aggregate of approximately $38,264 of interest accrued thereon, of which $550,000, $325,000, $50,000 and $200,000 of principal amount were issued as Series B, Series C, Series E and Series F Notes, respectively. The Series B Notes were issued in March 2011, mature June 2018 and, as a result of the completion of the Merger, are convertible into the Company’s common stock at a conversion price of $0.273773236 per share. The Series C notes were issued in September 2012, mature March 2016 and, as a result of the completion of the Merger, are convertible into the Company’s common stock at a conversion price of $0.273773236 per share. The Series E Notes were issued in June 2014, mature June 2018 and, as a result of the completion of the Merger, are convertible into the Company’s common stock at a conversion price of $0.410659854 per share. The Series F Notes were issued in December 2015, mature December 2019 and, as a result of the completion of the Merger, are convertible into the Company’s common stock at a conversion price of $0.547546472. Immediately following the Effective Time, the Notes were convertible into an aggregate of 3,821,571 shares of the Company’s common stock. All of the Notes bear interest at a rate of 1.0% per annum and are convertible into shares of Company’s common stock at the holder’s discretion. In the event a holder does not convert prior to a Note’s maturity date, the entire principal amount and all accrued interest are due and payable on such date. The Notes are subject to acceleration in the case of certain customary events of default, including failure to make payments on the Notes when due and certain bankruptcy events, and the conversion prices are subject to adjustment in the case of certain dilutive company events.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation These financial statements are expressed in U.S. dollars. The Company is organized into one operating and one reporting segment. The financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).
Going Concern Policy [Policy Text Block]	Going Concern As of December 31, 2015, the Company had $12,006,075 in cash and cash equivalents. Net cash used in operating activities was $9,599,585 for the year ended December 31, 2015. Net loss for the year ended December 31, 2015 was $23,820,675. As of December 31, 2015, the Company had working capital of $10,971,423. On January 8, 2016, in connection with the Merger described in Note 17, the Company paid $3,261,044 in severance payments to former executives and employees. The Company expects to incur losses for the next several years as it plans to develop its TSC product candidate. The Company is unable to predict the extent of any further losses or when the Company will become profitable, if at all. These financial statements have been prepared under the assumption that the Company will continue as a going concern. Due to the Company’s recurring and expected continuing losses from operations and its present financial resources, the Company has concluded that there is substantial doubt in the Company’s ability to continue as a going concern within one year of issuance on these financial statements without additional capital becoming available to fund planned Phase 2/3 and Phase 3 clinical trials, attain further operating efficiencies and, ultimately, to generate revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company will be required to raise additional capital within the next year to develop its trans sodium crocetinate product candidate and to fund operations at current cash expenditure levels. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business. If the Company is unable to obtain additional financing when needed, (i) it may be required to delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize itself on unfavorable terms.
Consolidation, Policy [Policy Text Block]	Consolidation The consolidated balance sheet at December 31, 2015 and 2014 consolidates the accounts of Canterbury, Hygeia, Paloma, VasculoMedics and ProElite, Inc. The consolidated statements of operations for the year ended December 31, 2015 and 2014 consolidate the accounts of Paloma and VasculoMedics from March 28, 2014, their date of acquisition. All significant intercompany balances were eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the Company’s consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. Although these estimates are based on the Company’s knowledge of current events and actions that the Company may undertake in the future, actual results may differ from such estimates and assumptions.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying value of certain of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value due to their short maturities. Other information about the Company’s assets and liabilities recorded at fair value is included in note 4.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. The Company records depreciation using the straight-line method over the following estimated useful lives: Equipment ( 3 – 5 Furniture and fixtures ( 5 Leasehold improvements Lesser of lease term or life of improvements
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets may not be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value.
Business Combinations Policy [Policy Text Block]	Business Combinations For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, at their fair values starting in the period when the acquisition is completed. Acquisition-related transaction costs are expensed as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets as of December 31, 2015 and 2014 consisted of an identifiable in-process research and development (“IPR&D”) project intangible asset arising from the acquisition of Paloma. Purchased intangible assets subject to amortization, are reviewed for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. Such events or circumstances include, but are not limited to, a significant decrease in the fair value of the underlying business, a significant decrease in the benefit realized from an acquired business, difficulties or delays in integrating the business or a significant change in the operations of an acquired business. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. An impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be recognized as an impairment charge. Research and development costs incurred after the acquisition are expensed as incurred.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit. The Company performs its annual goodwill impairment test during the fourth quarter of its fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit’s goodwill is less than the carrying value of the reporting unit’s goodwill.
Research and Development Expense, Policy [Policy Text Block]	Research and Development All research and development costs are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Compensation cost is measured and recognized at fair value for all stock-based payments, including stock options. For stock options, the Company estimates fair value using the Black-Scholes option-pricing model, which requires assumptions, such as expected volatility, risk-free interest rate, expected life, and dividends. Stock-based compensation expense is recognized net of estimated forfeitures on a straight-line basis over the related service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior, and is included in general and administrative expenses in the Company’s consolidated statements of operations. For 2015 and 2014, the Company estimated a forfeiture rate of nil when computing stock based compensation expense and reassesses its estimated forfeiture rate periodically based on new facts and circumstances. The Company accounts for equity instruments issued to non-employees in accordance with ASC Topic 718 and Emerging Issues Tax Force (“EITF”) Issue No. 96-18. The fair value of each stock option and warrant granted is estimated as of the grant date using the Black-Scholes option pricing model.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss attributable to the Company by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if all of the Company’s potential shares, warrants and stock options had been issued and if the additional shares were dilutive. The computation of diluted loss per share does not include the Company’s stock options or warrants as such securities have an antidilutive effect on loss per share. Because of their anti-dilutive effect, 7,793,072 and 8,472,013 shares of the Company’s common stock equivalents comprised of stock options and warrants for the years ended December 31, 2015 and 2014, respectively, have been excluded from the calculation of diluted earnings per share.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) The Company does not have items of other comprehensive income (loss) for the years ended December 31, 2015 or 2014; and therefore, comprehensive loss equals net loss for those years.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “ Revenue from Contracts with Customers ” of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligation in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In July 2015, the FASB delayed the effective date of this guidance. As a result, this ASU will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities have the option of applying either a full retrospective approach or a modified approach to adopt the guidance in the ASU. Although the Company currently does not have any revenues, it is evaluating the impact that this guidance will have on its results of operations, financial position and cash flows. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In February 2016, the FASB issued ASU 2016-02, Leases

Note 3 - Summary of Significa25

Note 3 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Property, Plant, and Equipment Usefu lLife [Table Text Block]	Equipment ( 3 – 5 Furniture and fixtures ( 5 Leasehold improvements Lesser of lease term or life of improvements

Note 4 - Acquisitions (Tables)

Note 4 - Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Paloma and Vasculo Medics [Member]
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Intangibles assets $ 6,449,628 Prepaids and other current assets 23,642 Property, plant and equipment 58,123 Goodwill 3,829,858 Accrued liabilities (135,000 ) Notes payable and accrued interest (1,151,725 ) Deferred tax liability (2,274,526 ) Net assets acquired $ 6,800,000

Note 5 - Property and Equipme27

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2015 2014 Computing equipment and office machines $ 38,785 $ 16,072 Furniture and fixtures 35,196 32,945 Leasehold improvements 5,157 60,017 Total 79,138 109,034 Less accumulated depreciation (21,143 ) (6,719 ) Property and equipment, net $ 57,995 $ 102,315

Note 6 - Intangible Assets, N28

Note 6 - Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2015 December 31, 2014 Gross Carrying Amount Accumulated Amortization Intangible Assets, net Gross Carrying Amount Accumulated Amortization Intangible Assets, net In-process research and development costs (IPR&D) $ 6,449,628 $ — $ 6,449,628 $ 6,449,628 $ — $ 6,449,628

Note 8 - Other Accrued Expens29

Note 8 - Other Accrued Expenses and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Other Current Liabilities [Table Text Block]	December 31, 2015 2014 Payroll related $ 91,302 $ 741,032 Professional fees 101,151 217,663 Board fees 55,938 55,000 Rent liability for facilities no longer occupied 424,155 808,418 Severance 221,183 0 Franchise taxes 97,644 0 Other 176,319 99,180 $ 1,167,692 $ 1,921,293

Note 9 - Stockholder's Equity (

Note 9 - Stockholder's Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Underlying Shares of Common Stock February 2, 2011 2,000 100.00 February 2, 2016 February 23, 2011 1,500 100.00 February 23, 2016 March 15, 2011 1,200 100.00 March 15, 2016 April 6, 2011 2,000 100.00 April 6, 2016 April 15, 2011 1,200 100.00 April 15, 2016 April 26, 2011 2,500 100.00 April 26, 2016 April 29, 2011 3,000 100.00 April 29, 2016 June 26, 2011 104,057 65.00 June 26, 2016 June 26, 2011 52,028 100.00 June 26, 2016 July 1, 2011 5,300 65.00 July 1, 2016 May 23, 2012 30,000 30.00 May 23, 2017 July 1, 2012 10,000 75.00 July 1, 2017 August 20, 2012 90,000 38.00 August 20, 2017 March 27, 2013 173,917 3.00 March 27, 2018 March 17, 2014 15,000 4.90 March 17, 2019 April 29, 2014 832,950 4.80 April 29, 2018 April 29, 2014 277,650 4.80 April 29, 2018 April 29, 2014 35,000 4.80 April 29, 2018 April 29, 2014 351,060 2.00 April 29, 2018 May 6, 2014 1,025,438 4.80 May 6, 2018 May 6, 2014 341,813 4.80 May 6, 2018 May 21, 2014 261,693 4.80 May 21, 2018 May 21, 2014 89,731 4.80 May 21, 2018 June 13, 2014 533,625 4.80 June 13, 2018 June 13, 2014 177,875 4.80 June 13, 2018 June 13, 2014 16,037 4.80 June 13, 2018 July 10, 2014 15,000 4.80 July 10, 2018 July 10, 2014 5,000 4.80 July 10, 2018 October 21, 2014 75,000 4.80 October 21, 2018 December 8, 2014 250,000 3.75 December 8, 2019 4,781,574
Schedule of Warrant Valuation Assumptions [Table Text Block]	2014 Risk-free interest rate 1.11 – 1.67% Expected life in years 4.0 – 5.0 Expected volatility 64% - 66% Expected dividend yield —

Note 10 - Stock-based Compens31

Note 10 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	December 31, 2015 December31, 2014 Research and development $ 597,554 $ 526,331 General and administrative 1,497,532 1,080,616 Total stock-based compensation expense $ 2,095,086 $ 1,606,947
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2015 2014 Risk-free interest rate 1.84% 1.82% - 2.03% Expected life in years 6.0 6.0 Expected volatility 68% 70% - 71% Expected dividend yield — —
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	Shares of Common Stock Weighted- Average Per Share Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Vested 1,861,953 $ 4.22 6.7 $ - Expected to vest 1,149,545 3.69 8.5 - Total 3,011,498 $ 4.01 7.4 $ -
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Outstanding Exercisable Number of Shares Weighted- Average Per Share Exercise Price Weighted- Average Remaining Contractual life (in years) Number of Shares Weighted- Average Per Share Exercise Price Weighted- Average Remaining Contractual life (in years) Outstanding at January 1, 2014 389,436 $ 11.77 3.9 367,110 $ 11.10 3.9 Granted 3,287,181 3.71 Exercised — — Forfeited or expired (28,370 ) 33.99 Outstanding at December 31, 2014 3,648,247 $ 5.44 8.8 1,072,111 $ 9.49 7.2 Granted 6,650 1.90 Exercised — — Forfeited or expired (643,399 ) 6.28 Outstanding at December 31, 2015 3,011,498 $ 4.01 7.4 1,861,952 $ 4.22 6.7

Note 11 - Commitments and Con32

Note 11 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Maturities of Contractual Obligations [Table Text Block]	Rental Commitments Payments due by period: One year $ 72,920 Two years 74,355 Three years 12,432 Four years — Five years — Over five years — Total $ 159,707

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, Deferred Tax Assets 2015 2014 Net operating loss carryforwards $ 25,165,014 $ 23,030,884 Stock option compensation 6,937,512 6,083,848 Other — 26,783 Valuation allowance (32,102,526 ) (29,141,515 ) Net deferred tax asset $ — $ — Deferred Tax Liabilities Intangible assets $ (2,274,526 ) $ (2,274,526 )
Summary of Operating Loss Carryforwards [Table Text Block]	December 31, 2015 2014 Combined NOL Carryforwards: Federal $ 63,013,194 $ 57,521,560 State 54,131,507 50,440,965
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2015 2014 Rate reconciliation: Federal tax benefit at statutory rate $ (8,337,236 ) (35.0 %) $ (6,009,398 ) (35.0 %) State tax, net of Federal benefit (1,368,216 ) (5.7 %) (986,051 ) (5.7 %) Change in valuation allowance 2,961,011 12.4 % 2,866,582 10.9 % Goodwill impairment 4,510,986 18.9 % — — Other 2,233,455 9.4 % 1,311,983 13.4 % Total provision $ — 0.0 % $ (2,816,884 ) (16.4 %)

Note 14 - Basic and Diluted N34

Note 14 - Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended 2015 2014 Basic and dilutive numerator: Net loss, as reported $ (23,820,675 ) $ (14,352,824 ) Denominator: Weighted-average shares outstanding 18,614,968 14,299,473 Net loss per share - basic and diluted $ (1.28 ) $ (1.00 )

Note 1 - Description of Busin35

Note 1 - Description of Business and Corporate History (Details Textual)	Mar. 28, 2014USD ($)shares	Mar. 07, 2014	Sep. 30, 2013shares	Dec. 31, 2015
Reverse Stock Split [Member ]
Stockholders' Equity Note, Stock Split, Conversion Ratio		100
Paloma [Member] | Notes Payable, Other Payables [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-term Debt and Accrued Interest | $	$ 1,151,725
Paloma [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,500,000
Vasculo Medics [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	220,000
Canterbury and Hygeia [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			1,150,116
Number of Businesses Acquired			2
Number of Phase I Clinicial Trials Completed				2

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Jan. 08, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Subsequent Event [Member]
Severance Costs	$ 3,261,044
Number of Operating Segments		1
Number of Reportable Segments		1
Cash and Cash Equivalents, at Carrying Value		$ 12,006,075	$ 21,883,887	$ 254,964
Net Cash Provided by (Used in) Operating Activities		(9,599,585)	(9,030,133)
Net Income (Loss) Available to Common Stockholders, Basic		(23,820,675)	$ (14,352,824)
Working Capital		10,971,423
Severance Costs		$ 967,683

Note 3 - Summary of Significa37

Note 3 - Summary of Significant Accounting Policies (Details Textual) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,793,072	8,472,013

Note 3 - Property and Equipment

Note 3 - Property and Equipment, Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2015
Equipment [Member] | Minimum [Member]
Property and equipment, estimated useful life	3 years
Equipment [Member] | Maximum [Member]
Property and equipment, estimated useful life	5 years
Furniture and Fixtures [Member]
Property and equipment, estimated useful life	5 years

Note 4 - Acquisitions (Details

Note 4 - Acquisitions (Details Textual) - USD ($)	Aug. 05, 2014	Mar. 28, 2014	Aug. 05, 2014	Dec. 31, 2014
Notes Payable, Other Payables [Member] | Paloma and Vasculo Medics [Member]
Long-term Debt Prepayment Penalties	$ 0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-term Debt and Accrued Interest		$ 1,151,725
Repayments of Assumed Debt and Accrued Interest	$ 1,331,007
Interest Expense, Debt, Excluding Amortization			$ 179,282
Notes Payable, Other Payables [Member] | Paloma [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-term Debt and Accrued Interest		1,151,725
Paloma and Vasculo Medics [Member]
Business Combination, Consideration Transferred		$ 6,800,000
Business Combination, Pro Forma Information, Expenses of Acquiree Since Acquisition Date, Actual				$ 846,910
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest				$ 14,352,824
Paloma [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		2,500,000
Vasculo Medics [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		220,000

Note 4 - Acquisitions - Summary

Note 4 - Acquisitions - Summary of Assets Acquired and Liabilities Assumed (Details)	Mar. 03, 2014USD ($)
Paloma and Vasculo Medics [Member]
Intangibles assets	$ 6,449,628
Prepaids and other current assets	23,642
Property, plant and equipment	58,123
Goodwill	3,829,858
Accrued liabilities	(135,000)
Notes payable and accrued interest	(1,151,725)
Deferred tax liability	(2,274,526)
Net assets acquired	$ 6,800,000

Note 5 - Property and Equipme41

Note 5 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
General and Administrative Expense [Member]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	$ (49,278)	$ (6,056)
Depreciation	$ 23,269	$ 11,924

Note 5 - Property and Equipme42

Note 5 - Property and Equipment, Net - Property and Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Computer Equipment and Office Machines [Member]
Property and equipment, gross	$ 38,785	$ 16,072
Furniture and Fixtures [Member]
Property and equipment, gross	35,196	32,945
Leasehold Improvements [Member]
Property and equipment, gross	5,157	60,017
Property and equipment, gross	79,138	109,034
Less accumulated depreciation	(21,143)	(6,719)
Property and equipment	$ 57,995	$ 102,315

Note 6 - Intangible Assets, N43

Note 6 - Intangible Assets, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
In Process Research and Development Costs (IPR&D) [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 3,035,000
Amortization of Intangible Assets	$ 0	554,338
Impairment of Intangible Assets (Excluding Goodwill)		6,670,345
Impairment of Intangible Assets, Finite-lived		$ 3,635,345

Note 6 - Intangible Assets, N44

Note 6 - Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
In Process Research and Development [Member]
Gross Carrying Amount	$ 6,449,628	$ 6,449,628
Accumulated Amortization
Intangible Assets, Net	$ 6,449,628	$ 6,449,628
Accumulated Amortization	$ 0	$ 554,338

Note 7 - Goodwill (Details Text

Note 7 - Goodwill (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Apr. 30, 2015
Share Price	$ 0.90	$ 1		$ 2.80
Market Capitalization	$ 16,700,000
Goodwill, Impairment Loss	11,070,991	$ 11,070,991
Goodwill	$ 985,000	$ 985,000	$ 12,055,991

Note 8 - Other Accrued Liabilit

Note 8 - Other Accrued Liabilities - Other Accrued Expenses and Other Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Payroll related	$ 91,302	$ 741,032
Professional fees	101,151	217,663
Board fees	55,938	55,000
Rent liability for facilities no longer occupied	424,155	808,418
Severance	221,183	0
Franchise taxes	97,644	0
Other	176,319	99,180
	$ 1,167,692	$ 1,921,293

Note 9 - Stockholder's Equity47

Note 9 - Stockholder's Equity (Details Textual)	Apr. 30, 2015$ / shares	Dec. 02, 2014USD ($)shares	Oct. 21, 2014USD ($)$ / sharesshares	Jul. 10, 2014USD ($)$ / sharesshares	Jun. 13, 2014$ / sharesshares	May. 21, 2014USD ($)$ / sharesshares	May. 06, 2014$ / sharesshares	Apr. 29, 2014USD ($)$ / sharesshares	Dec. 31, 2014$ / sharesshares	Apr. 29, 2015	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Sep. 30, 2015$ / shares	Dec. 31, 2013shares	Dec. 31, 2012shares
Notes Payable Dated July 9, 2012 Issued to Investor One [Member]
Debt Conversion, Converted Instrument, Shares Issued		7,764
Note Payable to High Yield Fund [Member]
Debt Conversion, Converted Instrument, Shares Issued						259,236
Debt Conversion, Original Debt, Amount | $						$ 500,000
Notes payable Dated July 9, 2012 Issued to Investor Two [Member]
Debt Conversion, Converted Instrument, Shares Issued		7,764
Notes Payable to 11 Investors [Member]
Debt Conversion, Original Debt, Amount | $		$ 50,000
Debt Instrument, Number of Investors Converting Debt		2
Director Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period												3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											0	438,131
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares												$ 3.70
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												10 years
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period											3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											6,650	2,849,050
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares											$ 1.90	$ 3.70
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											10 years
Investors [Member] | Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Term				4 years	4 years	4 years	4 years	4 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				15,000	533,625	261,693	1,025,438	832,950
Number of Shares of Common Stock Consisted in Unit				1	1	1	1	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				0.3	0.3	0.3	0.3	0.3
Share Price | $ / shares				$ 4	$ 4	$ 4	$ 4	$ 4
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 4.80	$ 4.80	$ 4.80	$ 4.80	$ 4.80
Placement Agent [Member] | Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				5,000	177,875	89,731	341,813	277,650
Placement Agent [Member] | Common Stock Warrants Issued April 29, 2014 [Member] | Tranche Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								35,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 4.80
A Law Firm [Member] | Warrants to Purchase Common Stock [Member]
Warrant Expense | $												$ 24,393
Independent Consultant [Member] | Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Term												5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 4.90			$ 4.90
Warrant Expense | $												$ 25,976
Class of Warrant or Right Vesting Period												1 year
Adjustments to Additional Paid in Capital, Change in Fair Value of Warrants Issued | $											$ (516)
Investor Relations Firm [Member] | Common Stock Warrants [Member] | General and Administrative Expense [Member]
Warrant Expense | $											496,010	$ 21,566
Investor Relations Firm [Member] | Common Stock Warrants [Member]
Class of Warrant or Right, Term									5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 3.75			$ 3.75
Term of Agreement with Counterparty									1 year
Warrants and Rights Outstanding | $											$ 517,576
Warrants to Purchase Common Stock [Member] | Convertible Notes Payable [Member] | Board of Directors Chairman [Member] | Financing Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								351,060
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 2
Warrants to Purchase Common Stock [Member] | Financing Transaction [Member] | Director [Member]
Warrant Expense | $												$ 107,395
Convertible Notes Payable [Member] | Board of Directors Chairman [Member] | Financing Transaction [Member]
Stock Issued During Period, Shares, Issued to Chairman in Connection with Settlement of Outstanding Debt								546,553
Number of Convertible Promissory Notes Converted								4
Debt Conversion, Original Debt, Amount | $								$ 1,050,000
Gains (Losses) on Extinguishment of Related Party Debt | $								$ (1,650,378)
Convertible Notes Payable [Member] | Financing Transaction [Member] | Director [Member]
Debt Conversion, Converted Instrument, Shares Issued			100,000									100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			75,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 4.80
Debt Conversion, Original Debt, Amount | $			$ 200,000									$ 200,000
Gains (Losses) on Extinguishment of Related Party Debt | $			$ (257,394)
Common Stock, Shares, Issued									18,614,968		18,614,968	18,614,968
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											6,650	3,287,181
Preferred Stock, Shares Authorized											5,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares											$ 0.001
Common Stock, Shares Authorized									1,000,000,000		1,000,000,000	1,000,000,000
Common Stock, Par or Stated Value Per Share | $ / shares									$ 0.001		$ 0.001	$ 0.001
Common Stock, Shares, Outstanding									18,614,968		18,614,968	18,614,968			890,837
Stock Issued During Period, Shares, New Issues				50,000	1,778,750	872,310	3,418,125	2,776,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											4,781,574
Share Price | $ / shares	$ 2.80										$ 1		$ 0.90
Proceeds from Issuance of Private Placement | $				$ 35,600,000
Net Proceeds from Issuance of Private Placement | $				31,900,000
Payments of Placement Agent Fees in Private Placement | $				3,600,000
Payments of Estimated Offering Expenses in Private Placement | $				$ 100,000
Number of Shares of Common Stock for Which Registration Statement is Filed for Offering and Resale of Common Stock				11,633,885
Gains (Losses) on Extinguishment of Related Party Debt | $												$ (1,907,772)
Gain (Loss) on Settlement of Notes Payable | $		$ (400,016)										$ (400,016)
Stock Issued During Period, Shares, Issued to Creditors in Connection with Settlement of Debt												160,056
Stock Issued During Period, Shares, Issued to Law Firm in Connection with Conversion of Outstanding Debt												53,457
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									3,648,247		3,011,498	3,648,247		389,436
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number									1,072,111		1,861,952	1,072,111		367,110
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares											$ 1.90	$ 3.71
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	1 year									90 days
Adjustments to Additional Paid in Capital, Change in Fair Value of Warrants Issued | $											$ (516)

Note 9 - Stockholder's Equity -

Note 9 - Stockholder's Equity - Warrants Outstanding and Exercisable (Details)	Dec. 31, 2015$ / sharesshares
Common Stock Warrants Issued on Date 1 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 2 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,500
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 3 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,200
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 4 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 5 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,200
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 6 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,500
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 7 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 8 [Member] | Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	104,057
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 65
Common Stock Warrants Issued on Date 8 [Member] | Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	52,028
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 100
Common Stock Warrants Issued on Date 9 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,300
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 65
Common Stock Warrants Issued on Date 10 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	30,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 30
Common Stock Warrants Issued on Date 11 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	10,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 75
Common Stock Warrants Issued on Date 12 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	90,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 38
Common Stock Warrants Issued on Date 13 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	173,917
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3
Common Stock Warrants Issued on Date 14 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.90
Common Stock Warrants Issued on Date 15 [Member] | Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	832,950
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 15 [Member] | Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	277,650
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 15 [Member] | Tranche Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	35,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 15 [Member] | Tranche Four [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	351,060
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2
Common Stock Warrants Issued on Date 16 [Member] | Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,025,438
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 16 [Member] | Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	341,813
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 17 [Member] | Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	261,693
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 17 [Member] | Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	89,731
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 18 [Member] | Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	533,625
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 18 [Member] | Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	177,875
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 18 [Member] | Tranche Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,037
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 19 [Member] | Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 19 [Member] | Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 20 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	75,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.80
Common Stock Warrants Issued on Date 21 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,781,574

Note 9 - Stockholder's Equity49

Note 9 - Stockholder's Equity - Warrant Assumptions (Details) - Warrants to Purchase Common Stock [Member]	12 Months Ended
	Dec. 31, 2014
Minimum [Member]
Risk-free interest rate	1.11%
Expected life in years	4 years
Expected volatility	64.00%
Maximum [Member]
Risk-free interest rate	1.67%
Expected life in years	5 years
Expected volatility	66.00%

Note 10 - Stock-based Compens50

Note 10 - Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015	Apr. 30, 2015	Mar. 05, 2015
Restorgenex Corporation 2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,500,000				2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,493,350
Restorgenex Corporation Non-plan Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,004,848
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 1.90	$ 1.90
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	54	54
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	1.90	$ 3.71
Share Price	$ 1		$ 0.90	$ 2.80
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 2,675,669

Note 10 - Stock-based Compens51

Note 10 - Stock-based Compensation - Summary of Stock Option Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Research and Development Expense [Member]
Stock-based compensation expense	$ 597,554	$ 526,331
General and Administrative Expense [Member]
Stock-based compensation expense	1,497,532	1,080,616
Stock-based compensation expense	$ 2,095,086	$ 1,606,947

Note 10 - Stock-based Compens52

Note 10 - Stock-based Compensation - Option Pricing Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Risk-free interest rate	1.84%
Risk-free interest rate		1.82%
Risk-free interest rate		2.03%
Expected life in years	6 years	6 years
Expected volatility	68.00%
Expected volatility		70.00%
Expected volatility		71.00%

Note 10 - Stock-based Compens53

Note 10 - Stock-based Compensation - Stock Options Vested and Expected to Vest (Details)	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares	1,861,952
Shares of common stock, vested, weighted-average per share exercise price (in dollars per share) | $ / shares	$ 4.22
Shares of common stock, vested, weighted-average remaining contractual life	6 years 255 days
Shares of common stock, vested, aggregate intrinsic value | $	$ 0
Shares of common stock, expected to vest (in shares) | shares	1,149,545
Shares of common stock, expected to vest, weighted-average per share exercise price (in dollars per share) | $ / shares	$ 3.69
Shares of common stock, expected to vest, weighted-average remaining contractual life	8 years 182 days
Shares of common stock, expected to vest, aggregate intrinsic value | $	$ 0
Shares of common stock, total (in shares) | shares	3,011,498
Shares of common stock, total, weighted-average per share exercise price (in dollars per share) | $ / shares	$ 4.01
Shares of common stock, total, weighted-average remaining contractual life	7 years 146 days
Shares of common stock, total, aggregate intrinsic value | $	$ 0

Note 10 - Stock-based Compens54

Note 10 - Stock-based Compensation - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Options outstanding (in shares)	3,648,247	389,436
Options outstanding, weighted-average per share exercise price (in dollars per share)	$ 5.44	$ 11.77
Options outstanding, weighted-average remaining contractual life	7 years 146 days	8 years 292 days	3 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,861,952	1,072,111	367,110
Shares of common stock, vested, weighted-average per share exercise price (in dollars per share)	$ 4.22	$ 9.49	$ 11.10
Shares of common stock, vested, weighted-average remaining contractual life	6 years 255 days	7 years 73 days	3 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	6,650	3,287,181
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.90	$ 3.71
Options exercised (in shares)
Options exercised, weighted-average per share exercise price (in dollars per share)
Options forfeited or expired (in shares)	(643,399)	(28,370)
Options forfeited or expired, weighted-average per share exercise price (in dollars per share)	$ 6.28	$ 33.99
Options outstanding (in shares)	3,011,498	3,648,247	389,436
Options outstanding, weighted-average per share exercise price (in dollars per share)	$ 4.01	$ 5.44	$ 11.77

Note 11 - Commitments and Con55

Note 11 - Commitments and Contingencies (Details Textual)	Sep. 04, 2014USD ($)ft²	Dec. 15, 2009USD ($)$ / sharesshares	Dec. 31, 2015shares	Dec. 31, 2015USD ($)	Sep. 21, 2015$ / shares
RES-440 and RES-529 [Member]
Long-term Purchase Commitment, Amount				$ 0
Buffalo Grove [Member] | Building [Member] | Long Term Operating Lease Agreement [Member]
Area of Real Estate Property | ft²	2,900
Lessee Leasing Arrangements Operating Leases Number of Extension Options	1
Lessee Leasing Arrangements, Operating Leases, Renewal Term	3 years
Operating Leases, Number of Months from Lease Inception that Monthly Rent is Not Required to Be Paid	5
Operating Leases Monthly Rent Expense	$ 6,000
Operating Leases Annual Rent Expense	72,000
Operating Leases Annual Increase in Rent Expense for First Year	6,100
Operating Leases Annual Increase in Rent Expense For Second Year and Thereafter	$ 6,200
David G. Schmidt v. Diffusion Pharmaceuticals, LLC [Member] | Scenario, Actual [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 3.50
David G. Schmidt v. Diffusion Pharmaceuticals, LLC [Member] | Plaintiff's Assertion of Entitled Conversion Price [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 1
David G. Schmidt v. Diffusion Pharmaceuticals, LLC [Member] | If Conversion Price $1.00 per Unit Rather Than $3.50 per Unit [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares		1,071,432.5
David G. Schmidt v. Diffusion Pharmaceuticals, LLC [Member]
Debt Conversion, Original Debt, Amount		$ 1,500,000
Loss Contingency, Damages Sought, Shares | shares			1,071,432.5

Note 11 - Commitments and Con56

Note 11 - Commitments and Contingencies - Contractual Obligations (Details)	Dec. 31, 2015USD ($)
Payments due by period:
One year	$ 72,920
Two years	74,355
Three years	12,432
Total	$ 159,707

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Jan. 31, 2016	Dec. 31, 2012
Subsequent Event [Member]
Common Stock, Shares, Outstanding			101,578,512
Income Tax Expense (Benefit)	$ 0	$ (2,816,884)
Deferred Income Tax Expense (Benefit)		$ (2,816,884)
Common Stock, Shares, Outstanding	18,614,968	18,614,968		890,837

Note 12 - Income Taxes - Deferr

Note 12 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Net operating loss carryforwards	$ 25,165,014	$ 23,030,884
Stock option compensation	$ 6,937,512	6,083,848
Other		26,783
Valuation allowance	$ (32,102,526)	(29,141,515)
Net deferred tax asset	0	0
Intangible assets	$ (2,274,526)	$ (2,274,526)

Note 12 - Income Taxes - Net Op

Note 12 - Income Taxes - Net Operating Loss Carryforwards (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Domestic Tax Authority [Member]
Combined NOL Carryforwards:
NOL carryforwards	$ 63,013,194	$ 57,521,560
State and Local Jurisdiction [Member]
Combined NOL Carryforwards:
NOL carryforwards	$ 54,131,507	$ 50,440,965

Note 12 - Income Taxes - Reconc

Note 12 - Income Taxes - Reconciliation of Income Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Rate reconciliation:
Federal tax benefit at statutory rate	$ (8,337,236)	$ (6,009,398)
Federal tax benefit at statutory rate	(35.00%)	(35.00%)
State tax, net of Federal benefit	$ (1,368,216)	$ (986,051)
State tax, net of Federal benefit	(5.70%)	(5.70%)
Change in valuation allowance	$ 2,961,011	$ 2,866,582
Change in valuation allowance	12.40%	10.90%
Goodwill impairment	$ 4,510,986
Goodwill impairment	18.90%
Other	$ 2,233,455	$ 1,311,983
Other	9.40%	13.40%
Income Tax Expense (Benefit)	$ 0	$ (2,816,884)
Total provision	0.00%	(16.40%)

Note 13 - Employee Benefit Pl61

Note 13 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 22,950	$ 0

Note 14 - Basic and Diluted N62

Note 14 - Basic and Diluted Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Basic and dilutive numerator:
Net Income (Loss) Available to Common Stockholders, Basic	$ (23,820,675)	$ (14,352,824)
Denominator:
Weighted-average shares outstanding (in shares)	18,614,968	14,299,473
Net loss per share - basic and diluted (in dollars per share)	$ (1.28)	$ (1)

Note 15 - Investment in Or-Ge63

Note 15 - Investment in Or-Genix Therapeutics, Inc. (Details Textual) - USD ($)	Apr. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Or Genix Therapeutics Inc [Member]
Cost Method Ownership Percentage	19.90%
Investment in Common Stock Shares	2,484,395
Payments to Acquire Investments	$ 250,000
Payments to Acquire Investments		$ 250,000

Note 16 - Former Employee Sev64

Note 16 - Former Employee Severance Expense (Details Textual) - USD ($)	Apr. 30, 2015	Apr. 29, 2015	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	1 year	90 days
Supplemental Unemployment Benefits, Severance Benefits			$ 221,183	$ 0

Note 17 - Subsequent Event (Det

Note 17 - Subsequent Event (Details Textual)	Jan. 08, 2016USD ($)$ / sharesshares	Jan. 07, 2016USD ($)	Mar. 23, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Diffusion LLC [Member] | Subsequent Event [Member] | Former Equity Holders of Diffusion LLC [Member]
Percentage of Common Stock Outstanding Owned	84.10%
Diffusion LLC [Member] | Subsequent Event [Member] | Equity Holders of RestorGenex [Member]
Percentage of Common Stock Outstanding Owned	15.90%
Diffusion LLC [Member] | Subsequent Event [Member] | Pre-closing Directors and Executive Officers of RestorGenex and Diffusion LLC [Member]
Percentage of Common Stock Outstanding Owned	16.60%
Period in Which Holders of Common Stock Have Agreed to Vote in Predetermined Manner and Hold Such Stock	180 days
Diffusion LLC [Member] | Subsequent Event [Member] | Diffusion LLC [Member]
Convertible Notes Payable	$ 1,125,000
Diffusion LLC [Member] | Subsequent Event [Member] | RES-440 [Member]
Business Combination, Period Following Merger in Which Receipt of Cash for Discontinued Product Assets Would Trigger Contingent Value Right Payements		5 years
Diffusion LLC [Member] | Subsequent Event [Member] | Convertible Debt [Member] | Series B Notes [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt, Principal	$ 550,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.273773236
Diffusion LLC [Member] | Subsequent Event [Member] | Convertible Debt [Member] | Series C Notes [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt, Principal	$ 325,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.273773236
Diffusion LLC [Member] | Subsequent Event [Member] | Convertible Debt [Member] | Series E Notes [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt, Principal	$ 50,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.410659854
Diffusion LLC [Member] | Subsequent Event [Member] | Convertible Debt [Member] | Series F Notes [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt, Principal	$ 200,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.547546472
Diffusion LLC [Member] | Subsequent Event [Member] | Convertible Debt [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt, Principal	$ 1,125,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt, Interest	$ 38,264
Debt Instrument, Convertible, Number of Equity Instruments	3,821,571
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Diffusion LLC [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Acquisitions | shares	82,963,544
Business Combination, Number of Shares Called by Each Previously Held Unit of Membership Interest | shares	3.652658
Business Combination, Number of Shares Called by Share Options Assumed | shares	14,952,101
Business Combination, Share Options Assumed, Weighted-average Exercise Price | $ / shares	$ 0.40
Severance Costs			$ 3,039,860
Business Combination, Number of Contingent Value Rights per Share Called by Each Previously Held Share of Common Stock		1
Business Combination, Contingent Value Right Payout Maximum		$ 50,000,000
Diffusion LLC [Member] | General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs				$ 1,193,115
Subsequent Event [Member]
Severance Costs	$ 3,261,044
Severance Costs				$ 967,683